Martinez Bueno A, Molina MA, Fielding A, et al. Disruptive mutations in TP53 associate with survival benefit in a PARPi trial in ovarian cancer. ESMO 2017, abstract LBA42.
Adjuvant alectinib verbetert DFS, maar effect op OS nog onduidelijk
mei 2024 | Longoncologie